The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.
May 6th 2024
Darolutamide uptake in metastatic hormone-sensitive prostate cancer has become routine both in doublet and triplet regimens in community urology practices.
Medical Crossfire®: Critical Questions on Diagnosis, Sequencing, and Selection of Systemic and Radioligand Therapy Options for Patients with GEP-NETs
View More
Medical Crossfire®: Expert Exchanges to Maximize Clinical Outcomes for Patients with CRPC Through Evidence-Based Personalized Therapy
View More
Everything You Need to Know About PARP Inhibitor Combinations in Prostate Cancer Care: Why? For Whom? And When?
View More
Advances In™: Targeting PSMA to Advance Diagnosis And Management Of Patients With Prostate Cancer
View More
Clinical Case Vignette Series: Integrating Recent Data into Practice to Improve Outcomes in Advanced Prostate Cancer
View More
Community Practice Connections™: Controversies and Conversations About HER2- Expressing Breast Cancer…Advances in Management of HER2-Low to -Positive Disease
View More
2023 ASCO Direct™ Highlights: Practice-Changing Data From the Leading Oncology Conference
View More
Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
Dialogues With the Surgeon on Integration of Systemic Therapies in Perioperative Settings for NSCLC: Looking at EGFR, ALK, IO, and Beyond…
View More
Tumor-Infiltrating Lymphocyte Therapy Advances Into Melanoma
View More
Studies Challenge Common Treatment Strategies in Prostate Cancer
May 8th 2014Two recent studies have raised questions about current trends in prostate cancer (PC) treatment, one supporting the employment of a little-used strategy-direct treatment of the primary tumor in men who have metastatic PC at diagnosis
Vitamin E, Selenium Can Greatly Increase Prostate Cancer Risk
May 6th 2014Despite being quite popular, the dietary supplements vitamin E and selenium do not protect men from developing prostate cancer, and in fact greatly increase risk in certain patients if taken at doses higher than those recommended
Dr. Pal on Sequencing Abiraterone and Enzalutamide in mCRPC
April 23rd 2014Sumanta Kumar Pal, MD, assistant professor, genitourinary cancers, City of Hope, discusses the results of a retrospective analysis of the effect of prior abiraterone use on the activity level of enzalutamide in men with metastatic castration-resistant prostate cancer (mCRPC).
Dr. Tagawa on CTCs in Neuroendocrine Prostate Cancer
April 11th 2014Scott T. Tagawa, MD, assistant professor of medicine, medical director, Genitourinary Oncology Research Program, Weill Cornell Medical College, discusses the molecular characterization of circulating tumor cells (CTCs) in neuroendocrine-positive prostate cancer.
Dr. Crawford on Predictive Tests in Prostate Cancer
April 4th 2014E. David Crawford, MD, professor, Urologic and Radiation Oncology, head, Section of Urologic Oncology, University of Colorado at Denver, discusses valuable prognostic and predictive tests to help urologists determine when to biopsy, when to rebiopsy, and how to direct treatment for patients with a positive biopsy.
Dr. Pelman on Determining Treatments for Newly Diagnosed Prostate Cancer
March 28th 2014Richard S. Pelman, MD, president of the American Association of Clinical Urologists and an urologist at the University of Washington Department of Urology, discusses techniques for selecting patients for radical prostatectomy or watchful waiting and active surveillance.
Hospital Admissions and Rectal Procedures are More Common After Radiotherapy Than Prostatectomy
March 18th 2014Men with clinically localized prostate cancer who were treated with radiotherapy were more likely, over the subsequent 5 years, to be admitted to a hospital, undergo rectal, anal, or open surgical procedures, or develop secondary malignancies than men treated with radical prostatectomy
Continue Screening for PSA But Treat Judiciously
March 17th 2014Screening for prostate-specific antigen (PSA) significantly cuts the death rate from prostate cancer, so America's medical community should continue to offer the test to appropriate men, but at the same time should work harder to avoid the screen's potential pitfalls.
Growing Role for Androgen-Targeting Therapies in CRPC
March 17th 2014A new generation of agents that target androgen synthesis and AR signaling have provided proof of concept and robust data to support the hypothesis that the androgen pathway remains an important factor throughout the management of CRPC.